



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



GDP-L-Fucose Synthase (human, recombinant)

Item No. 26695

Overview and Properties

Synonyms: GDP-4-keto-6-deoxy-D-Mannose-3,5-Epimerase-4-Reductase, Protein FX, Red Cell NADP(H)-Binding Protein, Short-Chain Dehydrogenase/Reductase Family 4E Member 1, Tissue Specific Transplantation Antigen P35B, TSTA3

Source: Recombinant N-terminal histidine-tagged GDP-L-fucose synthase purified from *E. coli*

Amino Acids: 2-321

Uniprot No.: Q13630

Molecular Weight: 37.98 kDa

Storage: -80°C (as supplied)

Stability: ≥1 year


Purity: *batch specific* (≥90% estimated by SDS-PAGE)

Supplied in: 50 mM HEPES, pH 8.0, with 150 mM sodium chloride and 10% glycerol

Protein Concentration: *batch specific* mg/ml

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Lane 1: MW Markers
Lane 2: GDP-L-Fucose Synthase (8 µg)
Lane 3: GDP-L-Fucose Synthase (4 µg)
Lane 4: GDP-L-Fucose Synthase (2 µg)

Representative gel image shown; actual purity may vary between each batch.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2019

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

GDP-L-Fucose synthase, encoded by the gene *TSTA3*, is an NADP(H)-binding protein that catalyzes the final step in the synthesis of GDP-L-fucose from GDP-D-mannose.^{1,2} It converts GDP-4-keto-6-deoxy-D-mannose to GDP-L-fucose via a two-step reaction consisting of epimerization followed by NADPH-dependent reduction. GDP-L-Fucose synthase exists as a homodimer and is comprised of an N-terminal NADPH-binding domain and a C-terminal substrate-binding domain. *TSTA3*^{-/-} mice exhibit increases in colonic inflammation, dysplasia, and epithelial permeability, which are reversed following addition of fucose to the diet.³ These mice also exhibit alterations in gut microflora and increased bacterial burden in colon transluminal tissue and feces when fed a normal diet versus a fucose-supplemented diet, and the colonic effects of *TSTA3* deletion can be reversed following administration of antibiotics. GDP-L-Fucose synthase has been identified as an autoantigen that can be recognized by CD4⁺ T cells derived from patients with multiple sclerosis.⁴ Expression of GDP-L-fucose synthase in primary tumor tissue samples from patients with esophageal squamous cell carcinoma (ESCC) positively correlates with increased clinical stage, lymph node metastasis, and poor prognosis.⁵

References

1. Tonetti, M., Sturla, L., Bisso, A., *et al.* Synthesis of GDP-L-fucose by the human FX protein. *J. Biol. Chem.* **271(44)**, 27274-27279 (1996).
2. Zhou, H., Sun, L., Li, J., *et al.* The crystal structure of human GDP-L-fucose synthase. *Acta Biochim. Biophys. Sin. (Shanghai)* **45(9)**, 720-725 (2013).
3. Wang, Y., Huang, D., Chen, K.-Y., *et al.* Fucosylation deficiency in mice leads to colitis and adenocarcinoma. *Gastroenterology* **152(1)**, 193-205 (2017).
4. Planas, R., Santos, R., Tomas-Ojer, P., *et al.* GDP-L-fucose synthase is a CD4⁺ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis. *Sci. Transl. Med.* **10(462)**, eaat4301 (2018).
5. Yang, J., Kong, P., Yang, J., *et al.* High *TSTA3* expression as a candidate biomarker for poor prognosis of patients with ESCC. *Technol. Cancer Res. Treat.* **17**, 1533033818781405 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM